文献速递临床试验与 GCP基础与转化研究

左甲状腺素联合缓释碘塞罗宁治疗甲状腺功能减退:随机对照双盲临床试验研究方案

Treatment of hypothyroidism with levothyroxine plus slow-release liothyronine: a study protocol for a randomized controlled double-blinded clinical trial.
PubMed 文献 · Trials · 2025-07-01

本研究为随机对照双盲临床试验方案,拟纳入100例经左甲状腺素单药治疗至少3个月且甲状腺功能正常的≥20岁甲状腺功能减退患者,随机分为左甲状腺素联合缓释碘塞罗宁组(75 µg左甲状腺素+25 µg缓释碘塞罗宁)与左甲状腺素单药组,疗程48周。预期联合治疗更接近甲状腺功能正常者的T3、T4水平及T3/T4比值,改善健康结局与生活质量,尤其对左甲状腺素单药治疗下持续有症状者。

要点

  • 方案拟纳入100例左甲状腺素单药治疗下甲状腺功能正常的甲状腺功能减退患者。
  • 联合组为75 µg左甲状腺素+25 µg缓释碘塞罗宁,对照组为左甲状腺素单药,疗程48周。
  • 主要评估包括甲状腺功能、代谢指标、生活质量、体成分及表观遗传标志物。

核心结论

  • 预期左甲状腺素联合缓释碘塞罗宁治疗比左甲状腺素单药治疗更接近甲状腺功能正常者的血清T3、T4水平及T3/T4比值,并改善健康结局与生活质量,尤其对左甲状腺素单药治疗下持续有症状的甲状腺功能减退患者。
  • 基因多态性测序可能识别对左甲状腺素单药治疗反应不佳的甲状腺功能减退患者。

研究设计与样本

  • 随机对照双盲临床试验方案,拟纳入100例年龄≥20岁、经左甲状腺素单药治疗至少3个月已达到并维持甲状腺功能正常的甲状腺功能减退患者。
  • 患者随机分为左甲状腺素联合缓释碘塞罗宁组(75 µg左甲状腺素+25 µg缓释碘塞罗宁)与左甲状腺素单药组,疗程48周。
  • 在基线及分配治疗后第12、24、48周随访评估。

关键数值与推荐

  • 联合组给药方案为75 µg左甲状腺素+25 µg缓释碘塞罗宁。
  • 疗程48周,随访节点为第12、24、48周。
  • 评估指标包括体重、心率、血压、心电图、生活质量(ThyPRO-39与SF-12)、静息能量消耗、体成分。
  • 血清指标包括TSH、总T3、总T4、游离T4、游离T3、总胆固醇、LDL、HDL、甘油三酯、空腹血糖、胰岛素、HbA1C、HOMA-IR、SHBG、烯醇化酶、LDH、CK、铁蛋白及代谢组学,在基线、24周和48周评估。
  • 表观遗传相关标志物在应答者与非应答者之间比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are emerging controversies regarding the priority of T4 + T3 combination therapy over standard care with levothyroxine (LT4) monotherapy in the management of hypothyroid subjects. Combination therapy with a slow-release form of liothyronine (SRT3) and levothyroxine may restore T3 concentrations and provide better outcomes, especially in individuals with persistent complaints despite having normal serum TSH levels. METHODS: One hundred patients aged ≥ 20 years with hypothyroidism who have achieved and maintained euthyroidism under LT4 monotherapy for at least 3 months will be randomized into two groups of LT4 + SRT3 combined therapy (75 µg LT4 + 25 µg SRT3) and LT4 monotherapy for 48 weeks. Participants will be evaluated at baseline and three subsequent follow-ups, 12, 24, and 48 weeks after treatment allocation. Before and after the intervention, body weight, heart rate, blood pressure, ECG, quality of life (by ThyPRO-39 and SF-12), resting energy expenditure, and body composition will be evaluated. Also, serum TSH, total T3, total T4, free T4, free T3, total cholesterol, LDL, HDL, triglycerides, fasting blood sugar (FBS), insulin, HbA1C, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), sex hormone-binding globulin (SHBG), enolase, lactate dehydrogenase (LDH), creatin kinase (CK), ferritin, and metabolomics will be assessed at baseline and compared with their corresponding values at 24 and 48 weeks. Epigenetic-related markers will be measured and compared between the responders and non-responders. CONCLUSION: It is expected that LT4 + SRT3 combined therapy more closely mimics the serum levels of T3, T4, and the T3/T4 ratio of euthyroid subjects than LT4 monotherapy, and improves health outcomes and quality of life, especially in hypothyroid patients with persistent symptoms under LT4 monotherapy. Genetic polymorphism sequencing may identify hypothyroid patients who are not responding well to levothyroxine alone. TRIAL REGISTRATION : Trial ID: 44220 ID: IRCT20100922004794N12 IRCT ID: IRCT20100922004794N12 Registration date: 2020-02-27 Expected recruitment start date: 2024-10-06 Expected recruitment end date: 2025-10-23.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Azizi F, Amouzegar A, Abdi H, et al. Treatment of hypothyroidism with levothyroxine plus slow-release liothyronine: a study protocol for a randomized controlled double-blinded clinical trial. Trials. 2025. PMID: 40598574. doi:10.1186/s13063-025-08940-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。